Research Article

The Efficacy of *Rosa damascena* on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial

S. Ali Al-Hadi Moravej 1,2, Asie Shojaii 1,3, Fataneh Hashem Dabaghian 1,2, S. Ferdows Jazayeri 1,2, S. Zahra Moravej 4, Ebrahim Khadem 5, Shahram Agah 6, and Roshanak Ghods 1,2

1Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran
2Department of Persian Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran
3Department of Traditional Pharmacy, School of Persian Medicine, Tehran, University of Medical Sciences, Tehran, Iran
4Ahvaz Jundishapur University of Medical Sciences, Department of Pharmacy, Ahvaz, Iran
5Department of Traditional Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran
6Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Roshanak Ghods; roshanakghods@gmail.com

Received 1 January 2021; Revised 18 April 2021; Accepted 2 August 2021; Published 13 August 2021

Academic Editor: Reza B. Jalili

Copyright © 2021 S. Ali Al-Hadi Moravej et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study aimed to appraise the potential effects of *Rosa damascena* preparation on nonalcoholic fatty liver disease (NAFLD). Design. In the randomized, double-blind placebo-controlled clinical trials, seventy-four patients with NAFLD were prescribed either 1 g *Rosa damascena* powder or placebo three times a day for 12 weeks. All patients were provided the lifestyle modification instructions and recommended following them precisely. ALT, AST, FBS, and lipid profiles were measured at the baseline after 12 weeks of studying. The Mann–Whitney *U* test was correctly used to compare the changes of variables among the groups. Results. Seventy-two patients completed the study in two groups. Sixty-seven patients were men, and the mean ± standard deviation of age was 40.11 ± 9.05 years. The *Rosa damascena* group showed a considerable decrease in the serum ALT (23.83 ± 24.82 vs. 16.19 ± 27.41, *p* = 0.042), waist circumference (99.73 ± 10.01 vs. 101.52 ± 8.84, *p* = 0.003), triglyceride (TG) (186.29 ± 76.75 vs. 184.47 ± 73.05, *p* = 0.001), cholesterol (167.47 ± 34.48 vs. 184.11 ± 33.54, *p* = 0.001), low-density lipoprotein (LDL) (99.17 ± 28.66 vs. 107.52 ± 25.42, *p* = 0.001), and elevation in serum high-density lipoprotein (HDL) (41.85 ± 6.56 vs. 39.20 ± 5.00, *p* < 0.007) compared to the control group. Improving fatty liver degree due to liver ultrasound was higher in the *Rosa damascena* group than the control group (*p* = 0.001). Conclusion. *Rosa damascena* meaningfully improves liver function in NAFLD. Hence, it can be recommended along with lifestyle modification for these patients. Further studies are recommended with a larger sample size.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) remains the universal cause of chronic hepatic disorders [1]. Fatty droplets typically occupy the liver in the notable absence of other causes of hepatic steatosis [2]. However, its pathophysiology is not clearly known, but the multiple-hit hypothesis properly including steatosis, active inflammation, insulin resistance, active hormones promptly released from adipose tissue, specific nutrients, gut microbiota, genetic, and epigenetic factors were respectfully suggested [3]. There is a relationship between metabolic syndrome and NAFLD [4]. It is a silent disease, but without adequately treating it undoubtedly delivers two severe outcomes: (1) intrahepatic: steatohepatitis, cirrhosis, and hepatocellular carcinoma. (2) Extrahepatic: diabetes mellitus type 2, hyperlipidemia, hypertension, ischemic heart disease, and extrahepatic cancers, especially colorectal carcinoma [5]. Its most favorable
treatment is lifestyle modification and drug prescription [6]. Antioxidant and immunomodulating drugs can treat this disease [7]. Persian medicine (PM) represents an ancient medical school which recommended some lifestyle modification methods (Seteye-Zaroorieh), herbal drugs, and hand practice or a’amal-e-yadavee such as massage and blood sampling methods (phlebotomy or fasd, cupping or hijamat, and leech therapy) for the treatment of disease [8]. Herbal preparation in PM was recommended for liver disease [9]. Rosa damascena is one of these cultivated plants that is planted and traditionally used in many countries such as Iran. The hepatoprotective effect of Rosa damascena is in terms of its components such as phenolic acid and flavonoid components [10]. Its petals have antioxidant and anti-inflammatory properties, and in animal studies, its effectiveness to clean the liver from accumulated triglycerides and prevent the inflammation of liver was shown [11]. Regarding PM principles, Rosa damascena has a pleasant odor; each aromatic herb reinforcing main organs such as the liver [12]. Since there is no clinical trial for the efficiency of Rosa damascena on NAFLD, this study was designated to show the Rosa damascena beneficial effect on liver enzymes and ultrasound grade in the patients with NAFLD.

2. Methods and Materials

2.1. Trial Design. This randomized, double-blind, placebo-controlled clinical trial was accomplished on two parallel groups of patients with NAFLD. Patients were appropriately allocated into two groups: intervention and placebo, by the block randomization method. The study protocol was approved by Medical Ethics Committee of Iran University of Medical Sciences (IR. IUMS REC.1398.406) and registered in Iran Clinical Trials Registry (ID: https://clinicaltrials.gov/ct2/show/IRCT20191006044994N1). Upon entering the study and completing it, all participants were evaluated in terms of blood pressure, waist circumference, height, and weight. A standard mercury calibrated sphygmomanometer was used to measure the blood pressure. Participants rested for 15 minutes, and in a sitting position, blood pressure was taken from their right hand. A rubber meter was properly used to accurately measure the waist circumference in the upright position. A standard meter and an accurate scale were properly used to accurately measure the height and weight. BMI was calculated according to standard formula: BMI = weight (kg)/height (m$^2$).

2.2. Participants. The patients who met the inclusion criteria were enrolled in Behest Clinic affiliated with Iran University of Medical Sciences in Tehran, Iran. The study began on 1st March 2020 and ended on November 2020.

2.2.1. Inclusion Criteria

The patients (18–80 y) with nonalcoholic fatty liver disease
Liver enzymes rising (AST > 38, ALT > 40)
Ultrasound report grade 1 or 2 or three of fatty liver

2.2.2. Exclusion Criteria. Acute or chronic liver disease, malignancy, pregnancy, uncontrolled diabetes mellitus, alcohol consumption, thyroid disease, psychological disorders, lactation, consumption of hepatotoxic drugs within the past 6 months, consumption of drugs which can affect the assessed biochemical tests of study within the previous 3 months (e.g., metformin, vitamin E, oral contraceptive pills, statins, and glucocorticoids), heart and adrenal insufficiency, and that did not want to willingly participate.

2.3. Intervention. After signing a written informed consent and taking a complete history of patients at the start of the study, they were randomly divided into two groups as case and control. Patients in both groups were given dietary recommendations due to classical medicine and recommended walking at an average speed for 40 minutes daily. The patients in the intervention group and who were in the placebo group received two capsules, each containing 500 mg of petal powder of Rosa damascena or toast powder, three times in a day, 30 minutes before a meal or 2 hours after the meal. Both groups were carefully followed for 12 weeks. Rosa damascena and placebo capsules were packaged in similar containers and labeled accordingly. Consumption of less than 80% of the drug during the trial was considered as drug intolerance, and the patient was excluded from the trial.

For concealment, sealed envelopes were used, so that the distinct number was recorded on similar envelopes. The drug and placebo were coded in similar capsules and identical packages with the same color and aroma. The patient and researcher were unaware of how the drug or placebo was coded.

This study aimed to appraise the potential effects of Rosa damascena preparation on liver enzymes in nonalcoholic fatty liver disease (NAFLD), especially ALT enzyme, at the beginning and the end of the 12th week of study.

Upon entering the study and completing it, all participants were evaluated in terms of blood pressure, waist circumference, height, and weight. A standard mercury calibrated sphygmomanometer was used to measure the blood pressure. Participants rested for 15 minutes, and in a sitting position, blood pressure was taken from their right hand. A rubber meter was properly used to accurately measure the waist circumference in the upright position. A standard meter and an accurate scale were properly used to accurately measure the height and weight. BMI was calculated according to standard formula: BMI = weight (kg)/height (m$^2$).

All these measurements were performed by a trained nurse. Blood samples were collected from the right hand of all participants after 12 hours of fasting. Complete blood count (CBC), biochemical (FBS, BUN, Cr, total cholesterol, TG, HDL, LDL, AST, and ALT) tests, and U/A (S. G) were precisely measured at weeks 0 and 12. For a significant amount of liver enzymes, photometric assay, and accurate measurement of blood glucose and other biochemical tests, an enzymatic colorimetric method using the standard kits (Pars Azmoun Company, Iran) was properly used. An experienced radiologist satisfactorily performed a liver ultrasound at the marked beginning and the end of controlled study.

2.3.1. Fatty Liver Score according to Ultrasound Grades

(1) Mild increased hepatic echogenicity with normal visualization of diaphragm and intrahepatic vessels
(2) Moderate increased hepatic echogenicity with mildly impaired visualization of diaphragm and intrahepatic vessels
(3) Severe increased hepatic echogenicity and poor or nonvisualization of diaphragm and intrahepatic vessels.

2.4. Drug and Placebo Preparation. *Rosa damascena* was collected from Marand city located in East Azerbaijan province and authenticated by a botanist from School of Pharmacy, Tehran University of Medical Science, Tehran, Iran (voucher no: pmp 584). The rose petals were carefully separated from the sepal and, after drying and crushing, were placed in 500 mg gelatin capsules. *Rosa damascena* capsules were used for better acceptance in patients. Placebo capsules were placed in 500 mg gelatin capsules.

2.5. Sample Size. Sufficient sample size was carefully calculated by proper utilization of pilot study information and the standard formula for accurately comparing two means and correctly observing 20 units of essential ALT difference between two specific groups with an alpha error of 0.05, power 80%, and with the expectation of 20% potential loss to proper follow-up. Ultimately, 74 patients (37 persons in each group) were enrolled.

2.6. Statistical Analysis. The patients with medication compliance as 80% or more entered the analysis. Data were carefully analyzed by SPSS software (version 17). The specific Kolmogorov–Smirnov test promptly confirmed the standard distribution of variables. The effective mean ± standard deviation or number and frequency percentage were properly used to typically describe the variables. The chi-square or Fisher exact test and independent t-test or Mann–Whitney U test were typically used to accurately compare the independent variables between two groups. Within-group analyses were typically performed using the Wilcoxon signed ranks test. P values less than 0.05 were considered statistically significant.

2.7. Safety Measures and Adverse Events. At the beginning of the study, a form was provided to patients in each group to record possible drug side effects such as gastrointestinal symptoms, constipation, diarrhea, and the effect on libido. CBC, BUN, and serum creatinine levels at weeks 0 and 12 were normal, and there were no significant changes in both groups. There was no report of severe adverse events in any patients.

3. Results

234 patients were enrolled, and 160 subjects who had not met the inclusion criteria were excluded. Seventy-four patients who met the inclusion criteria and agreed to participate in the study were divided into two groups. Thirty-seven patients were assigned to the intervention group and 37 patients to the control group. From each group, one individual was excluded in terms of COVID-19. In total, seventy-two cases completed the study. Thirty-six patients were in the *Rosa damascena* group and 36 patients in the placebo group (Figure 1).

The baseline characteristics of studying groups are summarized in Table 1. At the baseline, the frequency of all the primary and secondary outcome variables was statistically identical among groups except systolic blood pressure. To control the confounding effect of baseline systolic blood pressure, percent changes of systolic blood pressure were compared among groups. Regarding demographic characteristics, the mean age of participants was 41.5 ± 9.85 and 38.7 ± 8.07 years in the intervention and control groups, respectively. There were no significant differences in baseline demographic data and age, gender, and BMI between the two groups (Table 1).

Regarding laboratory indices, there were no significant differences in FBS, grade of NAFLD in ultrasound, ALT and AST, lipid profiles, and urine-specific gravity levels between two groups at the beginning of study (Tables 1 and 2).

Significant differences were observed due to baseline systolic blood pressure (p value = 0.004) (Table 1).

Following the patient in both groups, compliance with lifestyle did not indicate any significant differences among the groups. We followed the patients in both groups in terms of compliance with lifestyle modification every week and recalled them to do the diet and exercise instructions. Weight loss among 3–5% during 12 weeks was considered to assess the compliance of life and exercise modification between two groups; at the end of study, the weight change in the participants of two blocs was about 3–5% (Table 1).

3.1. Primary Outcome. Analyzing the results after 12 weeks reflected that there was a substantial reduction in the serum ALT levels in both groups. The percent decrease of ALT was significantly higher in the *Rosa damascena* group than in the control group (p = 0.042) (Table 1).

3.2. Secondary Outcomes. Except HDL, lipid profiles significantly decreased in the intervention group (TG, Chol, and LDL, p > 0.001), but HDL significantly increased in the intervention group (p < 0.007) (Table 1).

In both groups, the anthropometric factors such as weight, BMI, and WC reduced after 12 weeks, but WC was significantly decreased in the intervention group (p < 0.003) (Table 1).

Diastolic pressure significantly decreased in the intervention group (p = 0.001). Platelet count and SG were significantly decreased in the intervention group (platelet, p > 0.002 and SG, p > 0.001) (Table 1).

Moreover, there was a significant reduction in NAFLD grade in ultrasound in the *Rosa damascena* group compared to the placebo over the studying period (p value = 0.001) (Table 2).
4. Discussion

This study is the first randomized clinical trial investigating the effect of *Rosa damascena* petals on NAFLD. In this double-blind clinical trial, ordinary consumption of 3 g (two capsules, three times in a day) of *Rosa damascena* petal capsules for 12 weeks were compared to the placebo. There was no considerable gap in BMI among two groups. Various investigations indicated that 5–10% weight loss is considered for dietary consumption and exercise efficiency to improve

---

**Figure 1:** Participant flow.

**Table 1:** Amount variables at different times.

| Variables          | Group     | Baseline mean ± SD | P value | After 12 weeks mean ± SD | P value | Percent change mean ± SD | P value |
|--------------------|-----------|--------------------|---------|--------------------------|---------|--------------------------|---------|
| BMI (kg/m²)        | Rd        | 29.68 ± 3.66       | 0.064   | 28.46 ± 3.62             | 0.640   | 4.08 ± 3.96              | 0.102   |
|                    | Placebo   | 30.05 ± 3.88       |         | 29.22 ± 3.85             |         | 2.71 ± 3.18              |         |
| WC (cm)            | Rd        | 103.69 ± 10.64     | 0.967   | 99.73 ± 10.01            | 0.424   | 3.75 ± 2.76              | 0.003   |
|                    | Placebo   | 103.79 ± 8.89      |         | 101.52 ± 8.84            |         | 2.14 ± 2.71              |         |
| ALT (IU/L)         | Rd        | 69.05 ± 25.38      | 0.364   | 45.22 ± 19.45            | 0.262   | 31.52 ± 27.3             | 0.042   |
|                    | Placebo   | 66.41 ± 25.24      |         | 50.22 ± 20.60            |         | 18.66 ± 29.62            |         |
| AST (IU/L)         | Rd        | 1.82 ± 38.38       | 0.937   | 30.19 ± 9.83             | 0.787   | 13.40 ± 33.86            | 0.166   |
|                    | Placebo   | 37.44 ± 16.03      |         | 31.83 ± 12.60            |         | 11.33 ± 20.59            |         |
| Systolic BP (mmHg) | Rd        | 125.47 ± 13.47     | 0.004   | 118.52 ± 11.33           | 0.18    | 3.33 ± 4.18              | 0.001   |
|                    | Placebo   | 113.08 ± 11.70     |         | 113.47 ± 11.62           |         | −0.39 ± 3.00             |         |
| Diastolic BP (mmHg)| Rd        | 82.47 ± 12.17      | 0.97    | 82.47 ± 11.21            | 0.717   | 3.90 ± 7.78              | 0.001   |
|                    | Placebo   | 82.60 ± 7.20       |         | 82.60 ± 7.51             |         | 0.22 ± 3.85              |         |
| FBS (mg/dl)        | Rd        | 108.85 ± 26.31     | 0.251   | 103.11 ± 26.77           | 0.713   | 3.12 ± 16.14             | 0.103   |
|                    | Placebo   | 100.08 ± 25.12     |         | 103.94 ± 40.7            |         | −3.42 ± 15.89            |         |
| TG (mg/dl)         | Rd        | 225.44 ± 121.16    | 0.112   | 186.29 ± 76.75           | 0.764   | 9.61 ± 35.11             | >0.001  |
|                    | Placebo   | 190.70 ± 100.29    |         | 184.47 ± 73.05           |         | −3.67 ± 25.55            |         |
| Cholesterol (mg/dl)| Rd        | 189.14 ± 35.29     | 0.214   | 184.11 ± 33.54           | 0.048   | 14.66 ± 18.95            | >0.001  |
|                    | Placebo   | 189.14 ± 35.29     |         | 184.11 ± 33.54           |         | −14.94 ± 13.03           |         |
| HDL (mg/dl)        | Rd        | 36.82 ± 7.22       | 0.961   | 41.85 ± 6.56             | 0.044   | −14.94 ± 13.03           | 0.007   |
|                    | Placebo   | 35.85 ± 4.06       |         | 39.20 ± 5.00             |         | −9.83 ± 12.65            |         |
| LDL (mg/dl)        | Rd        | 112.91 ± 28.12     | 0.112   | 99.17 ± 28.66            | 0.208   | 3.28 ± 9.44              | >0.001  |
|                    | Placebo   | 112.08 ± 27.26     |         | 107.52 ± 12.60           |         | 19.97 ± 20.83            |         |
| Platelet (mm³ × 10³)| Rd        | 257.86 ± 43.69     | 0.333   | 237.36 ± 43.99           | 0.768   | 7.53 ± 9.11              | >0.002  |
|                    | Placebo   | 240.40 ± 78.53     |         | 238.25 ± 54.21           |         | 0.05 ± 17.88             |         |
| Urine SG           | Rd        | 1019.61 ± 7.04     | 0.276   | 1025.79 ± 5.82           | 0.027   | −0.60 ± 5.4              | >0.001  |
|                    | Placebo   | 1021.47 ± 8.86     |         | 1022.02 ± 7.5            |         | −0.5 ± 5.17              |         |

BMI, body mass index; WC, waist circumference; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FBS, fasting blood sugar; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SG, specific gravity, minus means to increase; Mann–Whitney U test.
the NAFLD [13]. Weight loss percent was less than 5% in both groups (Table 1).

The results showed that *Rosa damascena* could reduce liver enzymes (especially ALT), lipid profile, and blood pressure, meaningfully improve metabolic syndrome components, and increase urine SG.

Considering mutihit hypothesis, steatosis persists as the first event in the pathogenesis of NAFLD. Davoodi et al. showed that *Rosa damascena* could significantly reduce the final liver fat accumulation, TG, TC, and LDL-C serum concentrations, and hepatic enzymes in an experimental study [11]. Active inflammation is the second notable event in NAFLD pathogenesis [3]. *Rosa damascena* organic compositions such as flavonoids and phenols naturally have anti-inflammatory outcomes and severely inhibit destructive effects of active inflammation on the liver. Flavonoids components inhibit de novo lipogenesis and modulate intestinal microbiota imbalance [10].

Previous studies indicated that NAFLD increases hypertension, following cardiovascular diseases. Proper treatment of NAFLD can reduce cardiovascular disease incidence [14]. *Rosa damascena* naturally has cyanidin-3-O-B glucosides which efficiently remain as an antihypertensive agent in terms of inhibiting angiotensin-converting enzyme [15]. Many patients reported less depression and better sleep at the end of the study. These effects may be due to strengthening the vital organs, such as the brain, heart, and liver [16].

This study showed that urine-specific gravity increases after *Rosa damascena* consumption. Specific gravity represents an expression of urine concentration in terms of density. Fluid density critically depends on the sufficient number of solute particles present and their relative mass. Specific gravity measurement is used to reasonably assess the measurable quantity of solutes present in urine. It accurately reflects the ability of functioning kidneys to naturally produce the effective urine [17].

Another outcome was a reduction in the platelet count. Flavonoids contain many components, such 4-methylcatechol that is normally formed by human microflora. It poses a strong antiplatelet effect which can typically decrease the elevated incidence of cardiovascular diseases. This information can help explain the antiplatelet potential of orally given flavonoids containing formulas such as *Rosa damascena* [18].

In brief, after a favorable review of properties as mentioned above of *Rosa damascena*, it is typically recommended that before doing liver-destroying drugs such as halothane, advised patient should employ *Rosa damascena* for a certain period and typical dose along with lifestyle modification. This effect is due to synchronous properties of antioxidant activity and liver protector of *Rosa damascena*.

The safe dose of powder of *Rosa damascena* is up to 12 g [12]. Winther et al. found that the effective dose of *Rosa damascena* when used as the dried powder is 5 g per day [19]. We use 3 g or two 500 mg capsules three times a day. No significant reduction in the additional variables such as FBS might were due to the low doses of preparing in this study, and higher dosage or other types of preparation or more prolonged treatment time might be needed.

There were some limitations such as the short duration of the study and using *Rosa damascena* as a capsule for better acceptance in the patients (in the PM, its decoction form is recommended). The effect of *Rosa damascena* on liver histology (liver biopsy) was unstudied because it was quite invasive. The prevalence of the COVID-19 pandemic prevents the patients from participating in the study or causes them to leave the study.

### 5. Conclusion

This study showed that *Rosa damascena* petals powder consumption with a daily dose of 3 g for 12 weeks improved ALT enzyme, reduced fatty liver grade in ultrasound (Table 2), and better metabolic syndrome components in informed patients with NAFLD. Regarding the cost-effectiveness and availability of *Rosa damascena* and the lack of any reports for serious complications of this plant using, *Rosa damascena* can be recommended in patients with NAFLD. Further research with larger sample size and long-term follow-ups of patients, further research with a larger sample size can provide a stronger document about the usage of *Rosa damascena* as complementary medicine to treat the NAFLD.

### Data Availability

The data used to support the findings of this study are included within the article.

### Disclosure

This study was an active part of a Ph.D. thesis of Dr. Sayed Ali-Hahi Moravej.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

The study was supported by Iran University of Medical Sciences. The authors sincerely thank all patients and the

| Ultrasound grade | Baseline     | P value | After 12 weeks | P value |
|------------------|--------------|---------|----------------|---------|
|                  | Rd = 36      | Placebo = 36 |                |         |
| Grade 1          | 7            | 8       | 25             | 9       |
| Grade 2          | 27           | 24      | 0.635**        | 10      |
| Grade 3          | 2            | 4       | 0              | 5       |

**Person chi-square test.**
team that typically worked on this study, especially Mrs. Abdollahi, Dr. Behrooz Moghbelalhosein, and Dr. Amir Mohammadi Dehdezi.

References

[1] Y. M. Rayyan and R. F. Tayyem, “Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 12, no. 4, pp. 569–575, 2018.
[2] P. Bedossa, “Pathology of non-alcoholic fatty liver disease,” Liver International, vol. 37, pp. 85–89, 2017.
[3] E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism, vol. 65, no. 8, pp. 1038–1048, 2016.
[4] D. Kim, A. Touros, and W. R. Kim, “Nonalcoholic fatty liver disease and metabolic syndrome,” Clinics in Liver Disease, vol. 22, no. 1, pp. 133–140, 2018.
[5] A. Mantovani, E. Scorletti, A. Mosca, A. Alisi, C. D. Byrne, and G. Tarqher, “Complications, morbidity and mortality of nonalcoholic fatty liver disease,” Metabolism, vol. 111, Article ID 154170, 2020.
[6] N. Stefan, H.-U. Häring, and K. Cusi, “Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies,” The Lancet Diabetes & Endocrinology, vol. 7, no. 4, pp. 313–324, 2019.
[7] T. Shi, L. Wu, W. Ma et al., “Nonalcoholic fatty liver disease: pathogenesis and treatment in traditional Chinese medicine and western medicine,” Evidence-Based Complement and Alternative Medicine, vol. 2020, Article ID 8749564, 16 pages, 2020.
[8] M. Nimrouzi, A. Mahbodi, A.-M. Jaladat, A. Sadeghfard, and M. M. Zarshenas, “Hijamat in traditional Persian medicine,” Journal of Evidence-Based Complementary & Alternative Medicine, vol. 19, no. 2, pp. 128–136, 2014.
[9] W. Sun, M. H. Shahrajibian, and Q. Cheng, “Traditional Iranian and Arabic Herbal Medicines as natural anti-cancer drugs,” Agrociencia, vol. 54, no. 1, pp. 129–142, 2020.
[10] M. Akram, M. Riaz, N. Munir et al., “Chemical constituents, experimental and clinical pharmacology of Rosa damascena: a literature review,” Journal of Pharmacy and Pharmacology, vol. 72, no. 2, pp. 161–174, 2020.
[11] I. Davoodi, R. Rahimi, M. Abdollahi et al., “Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver,” Journal of Traditional and Complementary Medicine, vol. 7, no. 4, pp. 508–514, 2017.
[12] I. Nafis, Alshamel fi sanā’at tebbī‘at. Tehran, Iran: Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran, 2008.
[13] S. F. Jazayeri et al., “The efficacy of plantago major seed on liver enzymes in nonalcoholic fatty liver disease: a randomized double-blind clinical trial,” Evidence-Based Complement and Alternative Medicine, vol. 2021, Article ID 6693887, 7 pages, 2021.
[14] J.-H. Ryoo, Y. J. Suh, H. C. Shin, Y. K. Cho, J.-M. Choi, and S. K. Park, “Clinical association between non-alcoholic fatty liver disease and the development of hypertension,” Journal of Gastroenterology and Hepatology, vol. 29, no. 11, pp. 1926–1931, 2014.
[15] E.-K. Kwon, D.-Y. Lee, H. Lee et al., “Flavonoids from the buds of Rosa damascena inhibit the activity of 3-Hydroxy-3-methylglutaryl-coenzyme A reductase and angiotensin I-converting enzyme,” Journal of Agricultural and Food Chemistry, vol. 58, no. 2, pp. 882–886, 2010.
[16] M. AzamKhan, Aksir Azam, Vol. 2, The Institute for Medical History-Islamic and Complementary Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2013.
[17] C. C. Jacob, G. Dervilly-Pinel, G. Biancotto, and B. Le Bizec, "Evaluation of specific gravity as normalization strategy for cattle urinary metabolome analysis," Metabolomics, vol. 10, no. 4, pp. 627–637, 2014.
[18] L. Applová, J. Karlíčková, P. Warncke et al., “4-Methylcatechol, a flavonoid metabolite with potent antiplatelet effects,” Molecular Nutrition & Food Research, vol. 63, no. 20, Article ID 1900261, 2019.
[19] K. Winther, K. Apel, and G. Thamsborg, “A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial,” Scandinavian Journal of Rheumatology, vol. 34, no. 4, pp. 302–308, 2005.